Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy

A new strategy to coat oncolytic viruses in a bioengineered cell membrane with PD1 expression provides a clinical basis for combining oncolytic virotherapy with checkpoint inhibitors, resulting in a stronger antitumor immunity response.